► So, one of these could be your next car
► Which family EV comes out on top?
VW s new ID.3 takes on two other EVs with mainstream ambitions. But is the mass market ready for any of them? And are they ready for the mass market?
We brought together the ID.3 to face up to the popular Tesla Model 3 and the talented Polestar 2. Read on for our electric car three-way Giant Test.
VW ID.3: pre-flight briefing
Why is it here?
Because there are so many tough questions to be asked of the ID.3 that Emily Maitlis ought to be doing the interview. VW is betting a fair bit of its considerable farm on the ID.3 s success: does it have the desirability an EV It-Car needs? Is it as usable as a Golf? Is its quality up to scratch? That last point is a genuine concern, given the endless delays and niggles the ID.3 has suffered pre-launch.
Novartis International AG: Novartis receives complete response letter from U.S. FDA for inclisiran
The U.S. Food and Drug Administration (FDA) has not raised any concerns related to the efficacy or safety of inclisiran. The complete response letter is due to unresolved facility inspection-related conditions
No onsite inspection was conducted of the single third-party facility in question. If a facility inspection is needed, FDA will define an approach once safe travel may resume based on public health need and other factors
Novartis will work with FDA and the third-party manufacturing facility in Europe to complete the inclisiran review, to bring this potential first-in-class siRNA to patients in the U.S. as quickly as possible
NOVARTIS AG CHF0.50(REGD)
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF)
Potential Q1 2021 sNDA approval could make Entresto the first therapy indicated for use in treatment of patients with both major types of chronic heart failure: HFpEF and HFrEF; and the only chronic heart failure treatment studied in both conditions against active comparators
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.